This is an old revision of this page, as edited by Buidhe (talk | contribs) at 03:47, 23 December 2024 (added Category:Anti-diabetic drugs using HotCat). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 03:47, 23 December 2024 by Buidhe (talk | contribs) (added Category:Anti-diabetic drugs using HotCat)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)Dorzagliatin is a glucokinase activator that is being developed to treat diabetes. Unlike other diabetes drugs, it is intended to increase insulin sensitivity.
References
- Chow, Elaine; Wang, Ke; Lim, Cadmon K.P.; Tsoi, Sandra T.F.; Fan, Baoqi; Poon, Emily; Luk, Andrea O.Y.; Ma, Ronald C.W.; Ferrannini, Ele; Mari, Andrea; Chen, Li; Chan, Juliana C.N. (1 February 2023). "Dorzagliatin, a Dual-Acting Glucokinase Activator, Increases Insulin Secretion and Glucose Sensitivity in Glucokinase Maturity-Onset Diabetes of the Young and Recent-Onset Type 2 Diabetes". Diabetes. 72 (2): 299–308. doi:10.2337/db22-0708.
- Zhu, Dalong; Li, Xiaoying; Ma, Jianhua; Zeng, Jiao’e; Gan, Shenglian; Dong, Xiaolin; Yang, Jing; Lin, Xiaohong; Cai, Hanqing; Song, Weihong; Li, Xuefeng; Zhang, Keqin; Zhang, Qiu; Lu, Yibing; Bu, Ruifang; Shao, Huige; Wang, Guixia; Yuan, Guoyue; Ran, Xingwu; Liao, Lin; Zhao, Wenjuan; Li, Ping; Sun, Li; Shi, Lixin; Jiang, Zhaoshun; Xue, Yaoming; Jiang, Hongwei; Li, Quanmin; Li, Zongbao; Fu, Maoxiong; Liang, Zerong; Guo, Lian; Liu, Ming; Xu, Chun; Li, Wenhui; Yu, Xuefeng; Qin, Guijun; Yang, Zhou; Su, Benli; Zeng, Longyi; Geng, Houfa; Shi, Yongquan; Zhao, Yu; Zhang, Yi; Yang, Wenying; Chen, Li (May 2022). "Dorzagliatin in drug-naïve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial". Nature Medicine. 28 (5): 965–973.